Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.
Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist investor for complaining about the company's direction without c
Patients in England and Wales with multiple myeloma are celebrating a decision by NICE to relax strict restrictions on eligibility to receive Pfizer's Elrexfio.
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference
US Senators are concerned that Pfizer and Eli Lilly's recent forays into direct-to-consumer distribution of medicines via telehealth platforms could violate federal anti-kickback laws.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl